ARTICLE | Product Development
First-in-class drugs fill FDA’s 2021 class of new approvals
Products against new targets accounted for nearly one third of NMEs, and fewer of them were for cancer than you might think
December 23, 2021 11:38 PM UTC
Novel targets rather than new modalities or indications drove innovation this year, as first-in-class molecules filled FDA’s 2021 class of new drug approvals.
FDA’s Center for Drug Evaluation and Research (CDER) approved 49 new drugs in 2021, matching 2019’s approval rate but coming short of last year’s count of 53 (Figure 1)...
BCIQ Company Profiles